biotech
biotech Articles
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Published:
Last Updated:
Intra-Cellular Therapies has announced top-line results from its two late-stage trial in patients with bipolar depression.
Published:
Last Updated:
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Published:
Last Updated:
Avid Bioservices beat expectations around earnings, and it is adding customers and growing its backlog. One analyst has just reversed a prior downgrade and now believes that Avid shares could nearly...
Published:
Last Updated:
Adaptive Biotechnologies entered the market with a bang on Thursday, well above the high end of the expected price range.
Published:
Last Updated:
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Published:
Last Updated:
Aclaris Therapeutics shares sharply dropped early on Thursday after the firm announced results from its midstage trial in alopecia areata.
Published:
Last Updated:
Adaptive Biotechnologies intends to price 15 million shares to reslut in an initial public offering valued up to more than $327 million.
Published:
Last Updated:
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Last Updated:
Akorn shares dipped on Tuesday after the firm announced that it received a warning letter from the FDA related to the inspection of its Somerset, New Jersey, manufacturing facility in July and August...
Published:
Last Updated:
Minerva Neurosciences saw its shares jump on Monday after the firm announced results from a trial related to an insomnia treatment.
Published:
Last Updated:
Ocular Therapeutix shares jumped on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Dextenza to include the...
Published:
Last Updated:
Melinta Therapeutics shares nearly doubled early on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for...
Published:
Last Updated:
Analyst Yun Zhong looks at two treatments for Alzheimer Disease and other dementias that could beat the odds and be winners in treating these awful afflictions.
Published:
Last Updated:
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus price target.
Published:
Last Updated: